The Papanicolaou Society of Cytopathology Classification for Pulmonary Specimens: Application in Exfoliative Respiratory Cytology

Pooja Khari*, Sphruti Srivastava and Shalini Mullick
Department of Pathology, National Institute of Tuberculosis and Respiratory Diseases, Sri Aurobindo Marg Near Qutub Minar, Mehrauli, New Delhi - 110030

ABSTRACT

Background: Cytologic examination of specimens obtained from the respiratory tract is the primary and frequently used diagnostic technique in patients with respiratory symptoms or in those presenting with a pulmonary abnormality. Lung carcinoma is the leading cause of mortality in India. Hence, early diagnosis and effective treatment are keys to prolong the survival of lung cancer patients.

Methods: 100 consecutive samples were taken which included 66 samples of bronchial wash, 27 samples of brush and 7 samples of bronchoalveolar lavage. These were viewed independently by two pathologists to study the ease of applicability, reproducibility and role of Papanicolaou Society of Cytopathology classification for pulmonary specimens.

Result: The classification and terminology scheme recommend a six-tiered system comprising of non-diagnostic, negative, atypical, neoplastic (benign and neoplasms of low malignant potential), suspicious and positive for malignancy. In our study 43% were non-diagnostic, 33% were negative, 10% were atypical, 6% were suspicious for malignancy and 8% were malignant.

Conclusion: This classification system of respiratory cytology is easy to apply and interpret with minimal inter-observer variation. Standardized classification and terminology system provide a framework for consistent inter-intra departmental and inter institutional communication of diagnostic, prognostic and management information needed for consistent and optimal patient care.

Keywords: Papanicolaou, Bronchial Brush, Wash, Bronchoalveolar Lavage

Introduction

Lung carcinoma is the leading cause of mortality in India.\(^1\) In addition to primary tumour, lung is also a common site for metastatic tumours.\(^2\) Most lung cancer patients are diagnosed at an advanced stage of the disease, making curable surgery not an option. Hence, early diagnosis and effective treatment are keys to prolong the survival of lung cancer patients.\(^3\)

Cytologic examination of specimens obtained from the respiratory tract is a primary and frequently the initial diagnostic technique performed in patients with respiratory symptoms or in those presenting with a pulmonary abnormality. Both exfoliative cytology techniques and fine-needle aspiration (FNA) are used extensively for diagnosis of pulmonary lesions.\(^4\)

Currently, ancillary and molecular testing is also applied to these samples, further increasing their utility. However, lack of a standardized nomenclature and classification scheme has hampered communication between physicians managing patients.

1999, the PSC issued guidelines for the cytologic investigations of pulmonary lesions which included recommendations for a classification system \(^3\), but then it wasn’t routinely used. The PSC revised these guidelines in 2016 which proposed a six-category system for the diagnosis of cytologic samples obtained from the respiratory tract. These Categories includes non-diagnostic, negative (for malignancy), atypical, neoplastic, suspicious for malignancy, and positive for malignancy.\(^4\)

Materials and Methods

This prospective study was done in the Department of Pathology of a tertiary level centre for all respiratory diseases which receives a wide number of samples from respiratory tract. 100 consecutive samples were taken from the patients attending the pulmonary OPD and were independently viewed by two pathologists to study the ease of applicability, reproducibility and potential role of Papanicolaou Society of Cytopathology classification for pulmonary specimens, which includes bronchial washings, bronchial brush and bronchoalveolar lavage specimens. Ethical clearance was obtained from Institute’s ethics committee. 66 samples of bronchial wash, 27 brush and 7 BAL were included in the study. Histological follow-up was obtained in 49 cases. For statistical analysis of diagnostic accuracy, the surgical pathology diagnosis was used as the “gold standard”.

Samples were processed within 2 hours of receipt. The BAL/BW fluid were taken in a test tube and centrifuged
at 1500 revolutions per minute (rpm) for 10–15 minutes. The supernatant was discarded and three direct smears were prepared from the deposit. One smear was stained with Papanicolaou stain whereas the others were stained with H and E and May Grunwald Giemsa stain while Ziehl Neelsen staining was done in selected cases where indicated by morphological assessment.

Samples fulfilling the following criteria were included in the study i) samples from representative site, ii) no obstruction of cytomorphology by haemorrhage.

The PSC revised guidelines (2016) were used to obtain the result. These guidelines proposed a six-category system for the diagnosis of cytological samples obtained from the respiratory tract. These categories are non-diagnostic, negative (for malignancy), atypical, neoplastic, suspicious for malignancy and positive for malignancy (Table 1).[4]

**Results**

1. **Non-Diagnostic**: Out of 43 cases, we received biopsy of 17 cases. Amongst these 17, 12 cases (71%) were inconclusive in HPE also, however rest 5 cases (30%) turned out to be malignant. This was probably due to improper sample collection. Risk of malignancy in our study (30%) was lower than that seen in literature (54%). The high percentage for non-diagnostic reports especially for bronchial washings and BAL indicates the importance of sample collection. Proper sample collection can significantly increase the yield of these procedures, decreasing the need of invasive biopsy. There was no inter-observer variation.

2. **Benign**: There were 14 cases whose histopathology correlation were available, 11 cases (79%) were true negative, 3 (27%) were malignant in HPE. This data is comparable to literature review (24-43%) for risk of malignancy. This may be due to sampling error. There was no inter-observer variation. Patient selection is important for cytology. Standardization of reporting will help as negative cases may not require follow up but non diagnostic requires follow up.

3. **Atypical**: Out of 10 cases, we received 7 (70%) cases for HPE. All turned out to be malignant. Our proportion of malignant cases reported as atypical is higher than that seen in literature (54%). This can be attributed to (a) background of inflammation and degeneration obscuring morphology (b) lack of clinical and investigation data (c) inter-observer variation. Two out of ten had inter-observer variation. Both cases were discussed by the two pathologists to achieve consensus. One was reported as atypical whereas other was upgraded to neoplasm and was confirmed on HPE.

4. **Neoplastic**: There was unusual categorization on this spectrum of samples. Early presentation is uncommon in patients with malignancy. We did not encounter any benign neoplasm in this study as most common lesion (carcinoid tumour) is usually confirmed on biopsy.

5. **Suspicious of Malignancy**: There were three cases out of six available for histopathological correlation. All of them were malignant. This was little higher than literature (82%) due to paucity of cells.

6. **Malignant**: Malignant cases were in concordance with the other data (100%). This highlights the role of cytology in diagnosing lung cancer.

**Table 1: PSC Guidelines for Respiratory Cytology**[4,8]

| Diagnostic category and definition | Explanatory notes |
|-----------------------------------|-------------------|
| **I. Non diagnostic**             | This diagnostic category should be used when the specimen is acellular or when cells are not representative of the target being sampled. For example, bronchial cells and/or cartilage when the FNA target is a lymph node or lung mass. In addition, this category also applies to the FNA specimens of lymph node which show few lymphocytes, possibly from blood rather than a well sampled lymph node. It is recommended to process the entire specimen before designating a specimen “non diagnostic” |
| Insufficient and/or not           |                   |
| representative cellular material   |                   |
| for diagnosis.                    |                   |

| **II. Benign**                    | The lack of standardized adequacy criteria may explain the wide risk of malignancy range in this diagnostic category for both lung masses and lymph nodes. |
| The sample should be              |                   |
| representative of the clinical    |                   |
| lesion and benign. This category  |                   |
| also includes reactive lymph       |                   |
| nodes, granulomas, and other      |                   |
| inflammatory reactive processes.   |                   |
The Papanicolaou Classification for Pulmonary Specimens

| Diagnostic category and definition | Explanatory notes |
|-----------------------------------|-------------------|
| III. Atypical                     | This diagnostic category should be used when atypical epithelial cells are seen. However, the quantity or quality of these cells is insufficient to determine whether they represent reactive bronchial cells or pneumocytes vs. malignant cells. |
| Can be used for both lung masses  |                   |
| and lymph nodes                   |                   |
| IV. Neoplasm                      | A. This category includes neoplastic lesions in which the cytologic specimen is diagnostic of a specific benign neoplasm. B. This category should be used for cases where malignant neoplasm cannot be excluded. A majority of these cases will include neoplasms of low malignant potential. |
| A. Benign                         |                   |
| B. Undetermined malignant potential |                   |
| V. Suspicious of malignancy      | This diagnostic category should be used when the cellular atypia is favoured to be malignant but is not sufficient quantitatively or qualitatively for unequivocal malignancy. |
| (SM)                              |                   |
| VI. Malignant                     | Cytomorphology and/or immunohistochemistry (with antibodies validated in cytology samples) should be used to subclassify the tumour. |

Table 2: Results of present study.

| Categories                  | Bronchial wash | Bronchial wash | BAL | Total |
|-----------------------------|----------------|----------------|-----|-------|
| Non Diagnostic              | 34             | 04             | 05  | 43    |
| Benign                      | 20             | 12             | 01  | 33    |
| Atypical                    | 06             | 03             | 01  | 10    |
| Neoplastic                  | 00             | 00             | 00  | 00    |
| Suspicious of malignancy    | 06             | 00             | 00  | 06    |
| Malignancy                  | 00             | 08             | 00  | 08    |
| Total                       | 66             | 27             | 07  | 100   |

Fig. 1: Bronchial washing – showing respiratory cells (H and E, 400X).

Fig. 2: Bronchial washing – showing acid fast bacilli (ZN stain, 1000X oil immersion).
Discussion

Lung carcinoma is not only the leading cause of mortality in India, but lung is also a common site for metastatic tumours. Cytological examination of specimens obtained from the respiratory tract is the primary and frequently used diagnostic technique in patients with respiratory symptoms or in those presenting with a pulmonary abnormality. While occasional cytological specimens are obtained from the upper respiratory tract, the majority of pulmonary diagnostic cytology involves the study of the lower respiratory tract. Due to the complexity of the respiratory tract and the location of various target lesions, a variety of cytological techniques have been developed for the study of diseases of respiratory system. Both exfoliative cytology techniques and fine-needle aspiration (FNA) are used extensively for diagnosis of pulmonary lesions. While respiratory cytology is used predominantly for the study of neoplastic or potentially neoplastic diseases, it is also variably useful in the investigation of a variety of benign diseases including opportunistic infections, tuberculosis, sarcoidosis, industrial disease (e.g. asbestosis) and lung transplant rejection.

BW/lavage cytology is a widely accepted, safe, simple and minimally invasive technique to evaluate lung pathologies. Moreover, bronchial wash technique samples out peripheral areas of lung that are beyond the reach of bronchial brush. Currently, ancillary and molecular testing are also applied to these samples, further increasing their utility.

The Papanicolaou Society of Cytopathology (PSC) has been involved in diagnostic nomenclature for cytological material derived from other sites including thyroid, cervix and pancreaticobiliary system. In addition to proposing diagnostic criteria and categories, these classification systems have provided estimates of malignancy risk for each of the proposed categories. In 1999, the PSC issued guidelines for the cytological investigations of pulmonary lesions which included recommendations for a classification system, but then it wasn’t routinely used. However, the need for standardization remained until PSC 2016. Though the classification was released in 2016, on literature search we did not find any studies addressing to its applicability and use. Layfield et al tried to apply this classification to FNA samples from pulmonary nodules with inconsistent results. We did not find any studies using Papanicolaou classification on exfoliative cytology samples, therefore undertook this study.

While the collection and processing techniques for different respiratory cytology samples are now well established, same has not been done yet for reporting the samples. A major objective for these reporting systems was to increase
agreement among cytopathologist and to provide a uniform diagnostic terminology. These systems have been variably successful at improving intra-inter departmental and inter institutional communication of diagnostic, prognostic and management information needed for consistent and optimal patient care.

The PSC for respiratory cytology reinforces sample collection and patient selection. It is easy to apply without any modifications in routine practice and we found it to be easily reproducible. Regular use of this will also enable the clinicians to be aware of different categories.

Using PSC for respiratory cytology may be the first step in developing a systematic algorithm for diagnosis and planning management of patients suspicious of carcinoma lung as well as other pulmonary lesions. Also, while conducting this study we found not much work has been done in this field which encouraged us to study it more. The PSC for respiratory samples will contribute significantly to patient care like it has done for cervical, thyroid and pancreaticobiliary samples.

In our opinion, use of this classification will further help in standardizing the diagnosis of patients with presumed and proven lung cancer as well as in correct interpretation of reports and will also help in reviewing the cases reported at different institutes leading to more effective treatment management.

We recommend that it should be routinely utilized by all the pathologists even in centres with low respiratory cytology workload.

Cytology of pulmonary lesions is a reasonably accurate diagnostic tool with a sensitivity of 81.48% and specificity of 93.33% for both neoplastic and non-neoplastic lesions, if the sample obtained is appropriate, adequate and representative. Cytological evaluation must be assessed in conjunction with clinico-radiological findings. Cytology becomes more significant where biopsy is contraindicated.

**Conclusion**

The Papanicolaou 2016 classification is easy to use, and we found it to be easily reproducible. In our opinion use of this classification will further help in standardising the diagnosis of patients with presumed and proven lung cancer, leading to more effective treatment.

**Funding**

None

**Competing Interests**

None declared

**References**

1. Malik PS, Raina V. Lung cancer: Prevalent trends and emerging concepts. Indian J Med Res 2015;141:5-7.
2. Liu C, Wen Z, Li Y, Peng L. Application of Thin Prep Bronchial Brushing Cytology in the early diagnosis of Lung Cancer: A retrospective Study. Plos One 2014;9:1-7.
3. Suen KC, Abdul-Kerim FW, Kaminsky DB, et al. Papanicolaou Society of Cytopathologists TTask Force on Standards of Practice Guidelines of the Papanicolaou Society of Cytopathology for the examination of cytologic specimens obtained from the respiratory tract. Diagn cytologopathol 1999; 21:61-69.
4. Layfield LJ, Baloch Z, Elsheikh T, Litzky L, Rekhtman N, Travis WD, et al. Standardized terminology and nomenclature for respiratory cytology: The Papanicolaou Society of Cytopathology guidelines. Diagn Cytopathol 2016;44:399-409.
5. Solomides CC, Johnston WW, Elson CE. Respiratory tract. In: Bibbo M, Wilbur DC, editors. Comprehensive Cytopathology. 4th ed. St. Louis: Elsevier Saunders; 2015. p. 285-7.
6. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diag Cytopathol. 2008;36:425-437.
7. Nayar R, Wilbur D.C. The Pap Test and Bethesda 2014. Acta Cytologica 2015;59:121-132.
8. Pitman MB, Centeno BA, Ali SZ et al . Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology Guidelines. CytoJournal 2014;42:338-350.
9. Layfield LJ, Esebua M, Dodd L, Giorgadze T, Schmidt RL. The Papanicolaou Society of Cytopathology guidelines for respiratory cytology: Reproducibility of categories among observers. Cytojournal. 2018;15:22.
10. Ghildiyal S, Acharya S, Thakur B, Rawat J, Kumar R. Cytopathology of pulmonary lesions: A tertiary care center experience. J Cytol 2018;35:212-6.

*Corresponding author:
Dr. Pooja Khari, Address – 1898 A, Uday Chand Marg, KotlaMubarakpur, Delhi -110003 , India
Email: drpooja_1013@yahoo.in

Financial or other Competing Interests: None.